Sponsored by
A new preclinical study found that blocking a protein called MAGMAS, which helps tumor cells manage energy inside their mitochondria, may make glioblastoma cells more sensitive to temozolomide (TMZ). In laboratory and animal models, inhibiting MAGMAS weakened tumor cell survival and appeared to improve the effect of TMZ, radiation, and tumor treating fields, including in treatment-resistant cells.
This is early-stage research, but it adds to a growing body of evidence suggesting that targeting how tumor cells produce and manage energy may help overcome resistance to standard GBM treatments.